DK1397681T3 - Fremgangsmåde til identificering af midler til behandling af diabetes - Google Patents

Fremgangsmåde til identificering af midler til behandling af diabetes

Info

Publication number
DK1397681T3
DK1397681T3 DK02739056T DK02739056T DK1397681T3 DK 1397681 T3 DK1397681 T3 DK 1397681T3 DK 02739056 T DK02739056 T DK 02739056T DK 02739056 T DK02739056 T DK 02739056T DK 1397681 T3 DK1397681 T3 DK 1397681T3
Authority
DK
Denmark
Prior art keywords
diabetes
treatment
identifying agents
mnk2b
mnk2a
Prior art date
Application number
DK02739056T
Other languages
Danish (da)
English (en)
Inventor
Christina Bendz
Staffan Lake
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20284509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1397681(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Application granted granted Critical
Publication of DK1397681T3 publication Critical patent/DK1397681T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK02739056T 2001-06-18 2002-06-18 Fremgangsmåde til identificering af midler til behandling af diabetes DK1397681T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0102147A SE0102147D0 (sv) 2001-06-18 2001-06-18 New methods
PCT/SE2002/001268 WO2002103361A1 (en) 2001-06-18 2002-06-18 Method for identification of agents for the treatment of diabetes

Publications (1)

Publication Number Publication Date
DK1397681T3 true DK1397681T3 (da) 2007-07-16

Family

ID=20284509

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02739056T DK1397681T3 (da) 2001-06-18 2002-06-18 Fremgangsmåde til identificering af midler til behandling af diabetes

Country Status (13)

Country Link
US (1) US20030022241A1 (de)
EP (1) EP1397681B1 (de)
JP (1) JP4475945B2 (de)
AT (1) ATE356995T1 (de)
AU (1) AU2002311737B2 (de)
CA (1) CA2446284A1 (de)
CY (1) CY1107640T1 (de)
DE (1) DE60218843T2 (de)
DK (1) DK1397681T3 (de)
ES (1) ES2284879T3 (de)
PT (1) PT1397681E (de)
SE (1) SE0102147D0 (de)
WO (1) WO2002103361A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055664A2 (en) * 2001-01-12 2002-07-18 Exelixis, Inc. Modulating insulin receptor signaling
US20050080026A1 (en) * 2001-10-29 2005-04-14 Arnd Steuernagel Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
US20050202407A1 (en) * 2003-12-01 2005-09-15 Baylor College Of Medicine Methods and assays for screening anti-neoplastic therapeutic agents
CA2589902A1 (en) * 2004-12-02 2006-06-08 University Of Massachusetts Glucose-transport related genes, polypeptides, and methods of use thereof
KR20080107466A (ko) 2006-03-09 2008-12-10 파마코페이아, 인코포레이티드 대사 장애 치료용 8-헤테로아릴퓨린 ｍｎｋ2 억제제
EP1889847A1 (de) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidine zur pharmazeutischen Anwendung
US20130065914A1 (en) 2010-02-26 2013-03-14 Boehringer Ingelheim International Gmbh Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
AR080328A1 (es) 2010-02-26 2012-03-28 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
EA201201191A1 (ru) 2010-02-26 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
EP2917185B1 (de) 2012-11-09 2017-05-10 Evotec International GmbH Sulfoximinsubstituierte chinazoline für pharmazeutische zusammensetzungen
AU2014359456B2 (en) 2013-12-04 2019-01-24 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
WO2015091156A1 (en) 2013-12-17 2015-06-25 Boehringer Ingelheim International Gmbh Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions
AU2015257917C1 (en) 2014-05-07 2019-03-14 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
WO2017068064A1 (en) 2015-10-22 2017-04-27 Selvita S.A. Pyridone derivatives and their use as kinase inhibitors
AU2017239932A1 (en) * 2016-03-31 2018-10-25 Ocean University Of China Method of inhibiting high fat diet-related conditions
EP4225904A4 (de) 2020-10-09 2025-10-08 Univ Massachusetts Targeting von nrip1 zur linderung von stoffwechselerkrankungen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874231A (en) * 1994-08-22 1999-02-23 Mcgill University Methods of screening for non-hormone compounds which effect modulation of polypeptide translation
US6057117A (en) * 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3

Also Published As

Publication number Publication date
DE60218843T2 (de) 2007-07-12
ATE356995T1 (de) 2007-04-15
DE60218843D1 (de) 2007-04-26
EP1397681B1 (de) 2007-03-14
ES2284879T3 (es) 2007-11-16
SE0102147D0 (sv) 2001-06-18
AU2002311737B2 (en) 2007-06-21
CA2446284A1 (en) 2002-12-27
JP2005500033A (ja) 2005-01-06
US20030022241A1 (en) 2003-01-30
JP4475945B2 (ja) 2010-06-09
WO2002103361A1 (en) 2002-12-27
CY1107640T1 (el) 2013-04-18
EP1397681A1 (de) 2004-03-17
PT1397681E (pt) 2007-06-19

Similar Documents

Publication Publication Date Title
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
DK1426049T3 (da) Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
ATE464863T1 (de) Implantierbares medizinprodukt zur selektiven modulation der abgabe von mitteln in situ
BR0316487A (pt) Método todo de tratamento da rejeição de transplantes
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
BR0313792A (pt) Utilização de proteìna de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
ATE552031T1 (de) Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz
DE602004005814D1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
WO2003062273A3 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
ATE393917T1 (de) Identifikation von therapeutische verbindungen.
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
WO2002058532A3 (en) Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof
BRPI0408238A (pt) anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
DE50210279D1 (de) Screeningverfahren mit bnpi und dnpi
CY1105116T1 (el) Χρηση των il-6r/il-6 χιμαιρων στη νοσο του huntington
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
DE602004015321D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
DE60236894D1 (de) Behandlung von statin-nebenwirkungen mit uridinderivaten
DE50105253D1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
FR2816633B1 (fr) Methode de criblage d'agents susceptibles de traiter l'obesite